Granted Patent
B2
US 12,667,613 · App. 18/004,494 · Granted Jun 30, 2026
Nucleoside-modified RNA for inducing an immune response against SARS-CoV-2
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to compositions and methods for inducing an adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a SARS-CoV-2 antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a SARS-CoV-2 antigen, adjuvant, or a combination thereof.
Claims (12)
1 . A composition for inducing an immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject, the composition comprising at least one isolated nucleoside-modified mRNA encoding at least one SARS-CoV-2 antigen, wherein the at least one nucleoside modified mRNA comprises a nucleotide sequence transcribed from a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8.
2 . The composition of claim 1 , wherein the at least one isolated nucleoside-modified mRNA comprises pseudouridine or 1-methyl-pseudouridine.
3 . The composition of claim 1 , wherein the at least one isolated nucleoside-modified mRNA is a purified nucleoside-modified mRNA.
4 . The composition of claim 1 , wherein the composition further comprises an adjuvant.
5 . The composition of claim 1 , further comprising a lipid nanoparticle (LNP), wherein the at least one nucleoside-modified mRNA is encapsulated within the LNP.
6 . The composition of claim 1 , wherein the composition is a vaccine.
7 . A method of inducing an adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject comprising administering to the subject an effective amount of the composition of claim 1 .
8 . The method of claim 7 , wherein the at least one isolated nucleoside-modified mRNA comprises pseudouridine or 1-methyl-pseudouridine.
9 . The method of claim 7 , wherein the at least one isolated nucleoside-modified RNA is a purified nucleoside-modified mRNA.
10 . The method of claim 7 , wherein the method further comprises administering to the subject an effective amount of an adjuvant.
11 . The method of claim 7 , wherein the composition further comprises a lipid nanoparticle (LNP), wherein the at least one nucleoside modified mRNA is encapsulated within the LNP.
12 . The method of claim 7 , wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, inhalation, intranasal, and intramuscular.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2023
From: PARDI, NORBERT; WEISSMAN, DREW
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 062958/0834 →
Continuity (2)
Provisional Application
63049295
· Jul 8, 2020
References Cited (192)
US 2856420A
· Crawford, Jr.
· 1958
[cited by applicant]
US 3340299A
· Weintraub
· 1967
[cited by applicant]
US 3931430A
· Tada
· 1976
[cited by applicant]
US 6034137A
· Belloni
· 2000
[cited by applicant]
US 6333433B1
· Banerjee
· 2001
[cited by applicant]
US 6458381B1
· Sourovoi
· 2002
[cited by applicant]
US 8278036B2
· Kariko
· 2012
[cited by applicant]
US 8748089B2
· Kariko
· 2014
[cited by applicant]
US 8835108B2
· Kariko
· 2014
[cited by applicant]
US 9352042B2
· Heyes
· 2016
[cited by applicant]
US 9737619B2
· Ansell
· 2017
[cited by applicant]
US 9738593B2
· Ansell
· 2017
[cited by applicant]
US 9750824B2
· Kariko
· 2017
[cited by applicant]
US 9795566B2
· Oya
· 2017
[cited by applicant]
US 20030153081A1
· Tagawa
· 2003
[cited by applicant]
US 20050250723A1
· Hoerr
· 2005
[cited by applicant]
US 20060188490A1
· Hoerr
· 2006
[cited by applicant]
US 20080025944A1
· Hoerr
· 2008
[cited by applicant]
US 20090324584A1
· Hoerr
· 2009
[cited by applicant]
US 20100203076A1
· Fotin-Mleczek
· 2010
[cited by applicant]
US 20100291156A1
· Barner
· 2010
[cited by applicant]
US 20100305196A1
· Probst
· 2010
[cited by applicant]
US 20110300205A1
· Geall
· 2011
[cited by applicant]
US 20110305770A1
· Zhao
· 2011
[cited by applicant]
US 20130266640A1
· De Fougerolles
· 2013
[cited by applicant]
US 20130280305A1
· Kuboyama
· 2013
[cited by applicant]
US 20130295043A1
· Kallen
· 2013
[cited by applicant]
US 20150037326A1
· Butler-Ransohoff
· 2015
[cited by applicant]
US 20150118183A1
· Baumhof
· 2015
[cited by applicant]
US 20150118264A1
· Baumhof
· 2015
[cited by applicant]
US 20150306249A1
· Baumhof
· 2015
[cited by applicant]
US 20160166668A1
· Kallen
· 2016
[cited by applicant]
US 20160168227A1
· Kallen
· 2016
[cited by applicant]
US 20170326225A1
· Rauch
· 2017
[cited by applicant]
US 20180126003A1
· Hoerr
· 2018
[cited by applicant]
US 20180148727A1
· Grund
· 2018
[cited by applicant]
US 20180296663A1
· Hipp
· 2018
[cited by applicant]
US 20180303925A1
· Weissman
· 2018
[cited by applicant]
US 20180312545A1
· Baumhof
· 2018
[cited by applicant]
US 20190024096A1
· Schmid
· 2019
[cited by applicant]
US 20190274968A1
· Weissman
· 2019
[cited by applicant]
US 20200030432A1
· Ciaramella
· 2020
[cited by applicant]
US 20200163878A1
· Baumhof
· 2020
[cited by applicant]
US 20210228707A1
· Metkar
· 2021
[cited by examiner]
CN 110951756
· 2020
[cited by applicant]
CN 111088283
· 2020
[cited by applicant]
EP 1083232A1
· 2001
[cited by applicant]
EP 2567951
· 2013
[cited by applicant]
EP 3289083
· 2018
[cited by applicant]
JP 5331118
· 2013
[cited by applicant]
WO 1987007183
· 1987
[cited by applicant]
WO 1997003939
· 1997
[cited by applicant]
WO 1999005094
· 1999
[cited by applicant]
WO 2000030444
· 2000
[cited by applicant]
WO 2003053409
· 2003
[cited by applicant]
WO 2005060934
· 2005
[cited by applicant]
WO 2006138380A2
· 2006
[cited by applicant]
WO 2007024708
· 2007
[cited by applicant]
WO 2011143230
· 2011
[cited by applicant]
WO 2011153493
· 2011
[cited by applicant]
WO 2012016184
· 2012
[cited by applicant]
WO 2012068176
· 2012
[cited by applicant]
WO 2013016058
· 2013
[cited by applicant]
WO 2013086373
· 2013
[cited by applicant]
WO 2013143555
· 2013
[cited by applicant]
WO 2014028487
· 2014
[cited by applicant]
WO 2014160243
· 2014
[cited by applicant]
WO 2014160284
· 2014
[cited by applicant]
WO 2015164674A1
· 2015
[cited by applicant]
WO 2015177752A1
· 2015
[cited by applicant]
WO 2015199952
· 2015
[cited by applicant]
WO 2016145149
· 2016
[cited by applicant]
WO 2016176330
· 2016
[cited by applicant]
WO 2016210127
· 2016
[cited by applicant]
WO 2017015463
· 2017
[cited by applicant]
WO 2017021546
· 2017
[cited by applicant]
WO 2017048770
· 2017
[cited by applicant]
WO 2017049245
· 2017
[cited by applicant]
WO 2017070624A1
· 2017
[cited by applicant]
WO 2017070626
· 2017
[cited by applicant]
WO 2017075531A1
· 2017
[cited by applicant]
WO 2017140905
· 2017
[cited by applicant]
WO 2017173054
· 2017
[cited by applicant]
WO 2017182634
· 2017
[cited by applicant]
WO 2018132537
· 2018
[cited by applicant]
WO 2018191657
· 2018
[cited by applicant]
WO 2021178623
· 2021
[cited by applicant]
WO WO2021178623A1
· 2021
[cited by examiner]
Akinc et al., “A combinatorial library of lipid-like materials for delivery of RNAi therapeutics,” Nature Biotechnology 26(5):561-569, May 2008.
[cited by applicant]
Akinc et al., 2010, “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.” Mol Ther., 18(7): 1357-1364.
[cited by applicant]
Alabi C.A, et al., “Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,” PNAS, vol. 110, No. 32, , ISSN 0027-8424, pp. 12881-12886, Aug. 6, 2013.
[cited by applicant]
Anderson et al., 2010, “Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation.” Nucleic Acids Res 38:5884-5892.
[cited by applicant]
Anderson et al., 2011. “Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Research,” 39:9329-9338.
[cited by applicant]
Andries et al., “N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice,” Journal of Con…
[cited by applicant]
Basha et al., 2011, “Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.” Mol Ther, 19(12): 2186-2200.
[cited by applicant]
Belliveau et al., 2012, “Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA.” Mol Ther Nucleic Acids, 1: e37, 9 pages.
[cited by applicant]
Brito et al: “A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines”, Molecular Therapy, vol. 22, No. 12, Jul. 16, 2014 (Jul. 16, 2014) pp. 2118-2129.
[cited by applicant]
D.N. Nguyen et al: “Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery”, Proceedings of the National Academy of Sciences of the United States of America, vol. 109, No. 14, Apr. 3, 2012 (Apr. 3, 2012…
[cited by applicant]
Database EMBL [Online] EBI; Jan. 15, 2020 (Jan. 15, 2020), Zhang Y.-Z. et al: “Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome.”, XP055796635, Database accession No. MN908947.
[cited by applicant]
Freyn et al., 2020, “A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice,” Mol Ther. Jul. 8, 2020;28(7):1569-1584.
[cited by applicant]
Gao et al., 2020, “Rapid development of an inactivated vaccine candidate for SARS-CoV-2.” Science. Jul. 3, 2020;369(6499):77-81.
[cited by applicant]
Huang Chaolin et al: “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”, The Lancet, Elsevier, Amsterdam, NL, vol. 395, No. 10223, Jan. 24, 2020 (Jan. 24, 2020), pp. 497-506, XP08605031…
[cited by applicant]
Jayaraman, M et al., “Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo.”, Angewandte Chemie, (Jul. 10, 2012), vol. 51, No. 34, pp. 8529-8533, XP055063645.
[cited by applicant]
Karikó et al., “Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability,” Mol Ther, vol. 16, Issue 11, Nov. 2008, pp. 1833-1840.
[cited by applicant]
Karikó et al., “Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA,” Immunity, Aug. 2005, vol. 23, 165-175.
[cited by applicant]
Kariko et al., 2011. “Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleosidemodified, protein-encoding mRNA.” Nucleic Acids Research 39(21):e142, p…
[cited by applicant]
Kariko et al., 2012, “Increased Erythropoiesis in Mice Injected with Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin.” Mol Ther 20:948-953.
[cited by applicant]
Kirchdoerfer et al., 2016, “Pre-fusion structure of a human coronavirus spike protein,” Nature. Mar. 3, 2016;531(7592):118-21.
[cited by applicant]
Laczko et al., “A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice”, Cell Press, (Oct. 13, 2020), vol. 53, pp. 724-732, XP0862921…
[cited by applicant]
Lee et al., 2012, “Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.” Int J Cancer., 131(5): E781-90.
[cited by applicant]
Leung et al., 2012, “Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core.” J Phys Chem C Nanomater Interfaces, 116(34): 18440-18450.
[cited by applicant]
Maier et al., 2013, “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.” Mol Ther., 21(8): 1570-1578, XP055551712, ISSN: 1525-0016.
[cited by applicant]
Minor, 2015, “Live attenuated vaccines: Historical successes and current challenges,” Virology, 479-480: 379-392.
[cited by applicant]
Mui et al., 2013, “Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.” Mol Ther Nucleic Acids. 2, e139, 8 pages.
[cited by applicant]
Muthumani et al. “In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine,” Npj Vaccines (2016) 1, 16021, 11 pages.
[cited by applicant]
Pardi et al. (2018a). “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.” J Exp Med. Jun. 4, 2018;215(6):1571-1588.
[cited by applicant]
Pardi et al. (2018b). Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun. Aug. 22, 2018;9(1):3361.
[cited by applicant]
Pardi et al. (2017). “Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.” Nature. Mar. 9, 2017;543(7644):248-251.
[cited by applicant]
Pardi et al., “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes,” Journal of Controlled Release vol. 217, Nov. 10, 2015, pp. 345-351.
[cited by applicant]
Petsch et al., “Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection,” Nature Biotechnology 30:1210-1216, 2012.
[cited by applicant]
Sahin et al., “mRNA-based therapeutics—developing a new class of drugs,” Nature Reviews Drug Discovery vol. 13, pp. 759-780(2014).
[cited by applicant]
Semple et al., 2010, “Rational design of cationic lipids for siRNA delivery.” Nat Biotechnol., 28(2):172-176.
[cited by applicant]
Smatti et al., 2018, “Viral-Induced Enhanced Disease Illness,” Front Microbiol. Dec. 5, 2018:9:2991.
[cited by applicant]
Smith et al., (2020). “Immunogenicity of a DNA vaccine candidate for COVID-19.” Nat Commun. May 20, 2020;11(1):2601.
[cited by applicant]
Tam et al., “Advances in Lipid Nanoparticles for siRNA Delivery,” Pharmaceutics 5:498-507, 2013.
[cited by applicant]
Tam et al., 2013, “Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA.” Nanomedicine, 9(5): 665-74.
[cited by applicant]
Torrecilla, J et al., “Lipid Nanoparticles as Carriers for RNAi against Viral infections: Current Status and Future Perspectives.”, BioMed Research International., (Aug. 12, 2014), vol. 2014, No. 2014, pp. 1-18, XP05532…
[cited by applicant]
Wang et al., 2009, “Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins,” PLoS One 4: e8325, 13 pages.
[cited by applicant]
Weissman et al., 2000, “HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response,” J I…
[cited by applicant]
Weissman et al., 2013, “HPLC purification of in vitro transcribed long RNA,” Methods Mol Biol, 969: 43-54.
[cited by applicant]
Weissman, 2015, “mRNA transcript therapy,” Expert Rev Vaccines, 14: 265-281.
[cited by applicant]
Whitehead et al: “Synergistic Silencing: Combinations of Lipid-like Materials for Efficacious siRNA Delivery”, Molecular Therapy, vol. 19, No. 9, Sep. 1, 2011 (Sep. 1, 2011), pp. 1688-1694.
[cited by applicant]
Yu et al., (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. Aug. 14, 2020;369(6505):806-811.
[cited by applicant]
Zhao et al., 2016, “Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses,” Immunity. Jun. 21, 2016;44(6):1379-91.
[cited by applicant]